NET PROFIT (x1000 DKK)
EMPLOYEES
Chosa Oncology AB
Closing information (x1000 DKK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
178
|
365
|
986 |
| Earnings before taxes |
-6,231
|
-15,954
|
-27,472 |
| EBITDA |
-5,865
|
-15,275
|
-27,475 |
| Total assets |
10,774
|
13,048
|
18,634 |
| Current assets |
4,568
|
6,398
|
18,634 |
| Current liabilities |
1,800
|
1,353
|
12,590 |
| Equity capital |
8,974
|
11,695
|
6,044 |
| - share capital |
8,294
|
7,843
|
2,291 |
| Employees (average) |
1
|
1
|
4 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
83.3%
|
89.6%
|
32.4% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-56.2%
|
-119.5%
|
-142.1% |
| Current ratio |
253.8%
|
472.9%
|
148.0% |
| Return on equity (ROE) |
-69.4%
|
-136.4%
|
-454.5% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
0
|
-3
|
0 |
| Chg. No. of employees % |
0%
|
-75%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.